Repsol Reports 9-month Net Income Of EUR 1.94 Bln; Lifts Cash Dividend - Quick Facts

Spanish oil major Repsol S.A. (REPYY.PK) on Thursday reported that its nine-month net income was 1.939 billion euros, higher than 1.466 billion euros in the same period in 2019, prior to the COVID-19 crisis.

Repsol posted an adjusted net income, which specifically measures business performance, of 1.582 billion euros, compared to 1.637 billion euros in 2019.

Average production for the first nine months of the year was 576,000 barrels of oil equivalent per day.

Further, the company said its Board of Directors will propose to the next General Shareholders' Meeting a 5 percent increase in the cash dividend, to 0.63 per share, together with a reduction of 75 million shares, equivalent to 4.9 percent of the share capital. The company attributed the dividend growth to nine-month performance and the cash generation resulting from higher commodity prices.

Josu Jon Imaz, Repsol's Chief Executive Officer, said, "Our results have returned to pre-pandemic levels, driven by our efficient management and the implementation of our Strategic Plan. At the same time, we are making firm progress in our transformation to become carbon neutral by 2050."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT